Cabaletta Bio Inc (CABA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.57 (-0.39%), Market cap $0.54B, 52-week low–high $1.33 ~ $4.15.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T c
Financial statements, price targets, institutional (13F) holdings and related news for Cabaletta Bio Inc are updated in real time on BlackAll Trade.
Cabaletta Bio Inc trades at $2.57 (-0.39%). Real-time quotes and charts are available on BlackAll Trade.
Cabaletta Bio Inc has a market cap of about $0.54B.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product c